Condition category
Cancer
Date applied
30/03/2006
Date assigned
18/04/2006
Last edited
11/04/2016
Prospective/Retrospective
Prospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr Robert Amato

ORCID ID

Contact details

Genitourinary Oncology Clinic
The Methodist Hospital
6560 Fannin
Suite 2050
Houston
77030
United States of America

Additional identifiers

EudraCT number

ClinicalTrials.gov number

NCT00397345

Protocol/serial number

TV3/001/06

Study information

Scientific title

An international, randomised, double-blind, placebo-controlled, parallel group study to investigate whether a minimum of three doses of TroVax®, added to first-line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic clear cell renal adenocarcinoma

Acronym

TRIST

Study hypothesis

To investigate whether a minimum of three doses of TroVax, when added to the standard of care for locally advanced or metastatic clear cell renal adenocarcinoma prolong surival

Ethics approval

Not provided at time of registration

Study design

International, randomised, double-blind, placebo-controlled, parallel group study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type

Quality of life

Patient information sheet

Condition

Locally advanced or metastatic clear cell renal adenocarcinoma

Intervention

Dosing with TroVax via intramuscular injections into the upper arm muscle versus placebo

Intervention type

Drug

Phase

Not Specified

Drug names

Trovax

Primary outcome measures

Primary efficacy endpoints:
1. The survival event rate ratio in the TroVax arm versus the placebo in the modified intent to treat population based on the log of the hazard ratio derived from the Cox proportional hazards regression model. A Bayesian monitoring approach will be used for evaluating the event ratio.

The key objective of this study is to determine whether TroVax® is able to prolong survival in patients receiving first line standard of care if given sufficient time to induce an immune response. Prior studies indicate that three injections of TroVax® reliably induced an immune response to the 5T4 tumour antigen in almost all patients. In phase II studies, no patients discontinued treatment because of failure to tolerate TroVax®. In the event that any patient in this study does discontinue study medication before the third injection of TroVax® or placebo it will be assumed that they received the maximum tolerated number of injections and those patients will be included in the analysis of the primary objective.
All randomised patients who receive three injections of TroVax®/placebo or who cannot tolerate three injections will be included in this modified intent to treat analysis.
A confirmatory analysis will also be carried out using the intent to treat (ITT) population (and is included as a secondary endpoint).
Analysis is triggered by a predetermined number of deaths occurring after the third injection of TroVax® or placebo in the study population or when specified by an independent Data Safety Monitory Board based on analyses of interim data. (Deaths occurring before the third injection of TroVax® or placebo will not be included in the number triggering the primary efficacy analysis unless attributed by the investigator to TroVax® or placebo.)

Primary safety endpoints:
1. The number of adverse events (serious and non-serious) in the intent to treat population in the TroVax® versus the placebo arm
2. The laboratory variables (complete blood count and chemistry panel) in the intent to treat population in the TroVax® versus the placebo arm

Secondary outcome measures

1. The proportion of patients in the TroVax versus placebo arms in the modified intent to treat population with progression-free survival at 26 weeks based on a comparison of baseline and week 26 (+/- 1 week) radiological data and using response evaluation criteria in solid tumors (RECIST) criteria. Data will be adjudicated (blinded peer review).
2. The survival event rate ratio in the intent to treat population in the TroVax® versus the placebo arm, based on the log of the hazard ratio derived from the Cox proportional hazards regression model
3. Tumour response rates according to the investigator’s reported interpretation of the radiological reports based on RECIST criteria observed in the modified intent to treat population
4. The quality of life score for TroVax versus placebo as measured by quality of life questionnaire core 30 items (QLQ30) and EuroQoL questionnaires in the intent to treat and per protocol populations

Immunology endpoint:
1. Anti-5T4 antibody levels (additional measures of immune response including specific measures of cellular response will be investigated at some centres. Each will be the subject of a separate related protocol and informed consent for specific study sites and will be conditional upon regulatory and Institutional Review Board (IRB) or Ethics Committee approval before implementation).

Overall trial start date

01/09/2006

Overall trial end date

01/09/2009

Reason abandoned

Eligibility

Participant inclusion criteria

1. Signed informed consent. The patient must be competent to give written informed consent and comply with the protocol requirements.
2. Locally advanced or metastatic, histologically proven clear cell renal carcinoma
3. Primary tumour surgically removed (some residual advanced primary tumour may remain)
4. At least four weeks post surgery or radiotherapy
5. First-line. No prior therapy for renal cancer except surgery or radiotherapy
6. Measurable disease
7. Aged 18 years or more
8. Patient expected to survive a minimum of 12 weeks (i.e. in the opinion of the investigator there is a >90% probability that the patient will survive >12 weeks if treated with the selected standard of care)
9. Free of clinically apparent autoimmune disease (including no prior confirmed diagnosis or treatment for autoimmune disease including systemic lupus erythematosis, Grave’s disease, Hashimoto’s thyroiditis, multiple sclerosis, insulin-dependant diabetes mellitus or systemic (non-joint) manifestations of rheumatoid disease)
10. Total white cell count ≥3 x 10^9 /l and lymphocyte count ≥1 x 10^9 /l
11. Serum creatinine ≤1.5 times the upper limit of normal
12. Bilirubin ≤2 times the upper limit of normal and a serum glutamic pyruvic transaminase (SGPT) of ≤4 times the upper limit of normal
13. Women must be either post menopausal, or rendered surgically sterile or, if of child bearing potential, must have been practising a reliable form of contraception (oral contraception and barrier method) for at least three months prior to the first dose of TroVax® and must continue while they are being treated with TroVax®. Men must practise a reliable form of contraception (barrier or vasectomy) while they are being treated with TroVax®.
14. No acute changes on 12-lead electrocardiogram (ECG)
15. Ejection fraction documented as not less than 45% or no clinical suspicion that cardiac ejection fraction is less than 45%. (If clinical suspicion exists the ejection fraction should be measured according to local site procedures).

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

700

Participant exclusion criteria

1. Cerebral metastases. (Known from previous investigations or clinically detectable)
2. Previous exposure to TroVax®
3. Serious infections within the 28 days prior to entry to the trial
4. Known to test positive for human immunodeficiency virus (HIV) or hepatitis B or C
5. Life threatening illness unrelated to cancer
6. History of allergic response to previous vaccine vaccinations
7. Known allergy to egg proteins
8. Known hypersensitivity to neomycin
9. Participation in any other clinical trial of a licensed or unlicensed drug within the previous 30 days or during the course of this trial
10. Previous malignancies within the last 10 years other than successfully treated squamous carcinoma of the skin or in situ carcinoma of the cervix treated with cone biopsy
11. Previous history of major psychiatric disorder requiring hospitalization or any current psychiatric disorder that would impede the patient’s ability to provide informed consent or to comply with the protocol
12. Oral corticosteroid use unless prescribed as replacement therapy in the case of adrenal insufficiency
13. Ongoing use of agents listed in locally approved prescribing information as causing immunosuppression
14. Prior history of organ transplantation
15. Pregnancy or lactation

Recruitment start date

01/09/2006

Recruitment end date

01/09/2009

Locations

Countries of recruitment

Belgium, France, Germany, Israel, Netherlands, Poland, Romania, Russian Federation, Spain, Switzerland, Ukraine, United Kingdom, United States of America

Trial participating centre

Genitourinary Oncology Clinic
Houston
77030
United States of America

Sponsor information

Organisation

Oxford BioMedica

Sponsor details

The Oxford Science Park
Oxford
OX4 4GA
United Kingdom

Sponsor type

Industry

Website

http://www.oxfordbiomedica.co.uk

Funders

Funder type

Industry

Funder name

Oxford BioMedica UK Ltd.

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

11/04/2016: No publications found, verifying study status with principal investigator.